Apellis Pharmaceuticals Q1 2025 10-Q Filing
Ticker: APLS · Form: 10-Q · Filed: May 7, 2025 · CIK: 1492422
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
Related Tickers: APLS
TL;DR
APLS Q1 2025 10-Q filed. Financials look solid, check details.
AI Summary
Apellis Pharmaceuticals, Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's financial statements reflect various assets and liabilities, including common stock and convertible notes. Key financial activities and disclosures are detailed within this 10-Q filing.
Why It Matters
This filing provides investors with a detailed look at Apellis Pharmaceuticals' financial health and operational status as of the first quarter of 2025.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the financial quarter being reported.)
- 2019-09-16 — Convertible Notes Date (Date related to the 'TwoThousandNineteenConvertibleNotesMember'.)
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250507 (date) — Filing date
- 001-38276 (company) — SEC File Number
- 271537290 (company) — EIN
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on 20250507.
What is the company's SEC File Number?
The SEC File Number for Apellis Pharmaceuticals, Inc. is 001-38276.
What is the fiscal year end for Apellis Pharmaceuticals, Inc.?
The fiscal year end for Apellis Pharmaceuticals, Inc. is 1231.
What is the business address of Apellis Pharmaceuticals, Inc.?
The business address is 100 FIFTH AVENUE, WALTHAM, MA 02451.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 regarding Apellis Pharmaceuticals, Inc. (APLS).